18:50 , Oct 27, 2017 |  BC Week In Review  |  Clinical News

Bone's Allob meets in Phase I/IIa for delayed-union bone fractures

In September, Bone Therapeutics S.A. (Euronext:BOTHE) reported interim data from a Phase I/IIa trial in 16 patients with delayed-union fractures of long bones showing that Allob met the primary endpoint of improving radiological Tomographic Union...
07:00 , Oct 24, 2016 |  BC Week In Review  |  Clinical News

Allob: Additional Phase IIa data

Additional data from 8 patients with symptomatic degenerative lumbar disc disease that required interbody fusion in an open-label, Belgian Phase IIa trial showed that a single implantation of Allob mixed with bioceramic granules into the...
07:00 , May 9, 2016 |  BC Week In Review  |  Clinical News

Allob: Completed Phase IIa enrollment

Bone Therapeutics completed enrollment of 18 patients in an open-label, Belgian Phase IIa trial evaluating a single implantation of Allob mixed with bioceramic granules. The study enrolled patients with symptomatic degenerative lumbar disc disease that...
08:00 , Mar 7, 2016 |  BC Week In Review  |  Clinical News

Allob: Phase IIa data

Data from the first patient with symptomatic degenerative lumbar disc disease that required interbody fusion in an open-label, Belgian Phase IIa trial showed that a single implantation of Allob mixed with bioceramic granules into the...
02:24 , Feb 5, 2015 |  BC Extra  |  Financial News

Bone Therapeutics raises EUR 32.2M in IPO

Regenerative medicine play Bone Therapeutics S.A. (Euronext:BOTHE) raised EUR 32.2 million ($36.5 million) through the sale of 2 million shares at EUR 16 in an IPO, giving it a market cap of EUR 104.8 million...
08:00 , Feb 2, 2015 |  BC Week In Review  |  Clinical News

Allob: Phase I/IIa data

Data from the first cohort of 4 patients with non-infected, delayed-union fractures of long bones in an open-label, European Phase I/IIa trial showed that a single implantation of Allob into the fracture site led to...
07:00 , Sep 29, 2014 |  BC Week In Review  |  Clinical News

Allob: Phase IIa started

Bone Therapeutics began an open-label, Belgian Phase IIa trial to evaluate a single dose of Allob mixed with bioceramic granules in about 16 patients with symptomatic degenerative lumbar disc disease that requires interbody fusion. Allob...
07:00 , Jul 14, 2014 |  BC Week In Review  |  Clinical News

Allob: Phase I/IIa started

Bone Therapeutics began an open-label, European Phase I/IIa trial to evaluate a single implantation of Allob in 32 patients with non-infected, delayed-union fractures of long bones. A delayed-union fracture is defined as absence of healing...